Alnylam Pharmaceuticals, Inc. vs Harley-Davidson Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Harley-Davidson Inc trades at $26.91 (market cap $2.78B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.6× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HOG | |
|---|---|---|
Market Cap | $29.60B | $2.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $31.03 |
52-Week Low | $205.48 | $17.19 |
Enterprise Value | $27.56B | $3.19B |
Dividend Yield | — | 2.75% |
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →